AstraZeneca adds to EU's vaccine shortages woes

25 January 2021
european_commission_large

Anglo-Swedish drugmaker AstraZeneca (LSE: AZN) has warned the European Commission (EC) to expect delays to the supply of its COVID-19 vaccine.

Reduced yields at a manufacturing site have been blamed for the issue, which reportedly could cut first-quarter deliveries by 60% to 31 million doses. The population of the EU is nearly 450 million.

AstraZeneca's vaccine is yet to be authorized by the EC, although a decision is expected by the end of the month, and the EC has pre-ordered up to 400 million doses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology